Proactive Investors - Run By Investors For Investors

Pressure BioSciences chief presents rosy view of growth prospects in podast interview

CEO says company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc.
scientists in lab
New distribution deal with rival creates new sales opportunities

Richard Schumacher, chief executive of Pressure BioSciences Inc (OTCMKTS:PBIO), a Massachusetts-based life science group which makes laboratory devices, is on the road, touting the expansion of the firm’s business.

The chief of this maker of instruments which utilise pressure to control bio-molecular interactions said his company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc., an Illinois-based designer of scientific instruments.

Schumacher said on Tuesday in an interview with Uptick Newswires "Stock Day" podcast: “We believe we have set the table to facilitate even greater revenues with the deployment of an experienced, trained, and dedicated field sales team, the acquisition of the BaroFold, Inc. assets – including 8 important patents that integrate well with our own seventeen patents, and our very recently announced co-marketing and distribution relationship with ISS Inc.”

Pressure BioSciences reached the two-year agreement with ISS last month.

One of the products ISS makes is a spectrophotometer -- an instrument used in drug discovery and development -- the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As its name suggests, Pressure Bio, meanwhile, manufactures automated pressure generators for laboratories which can increase and decrease pressure “like a light switch.”

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000 and US$50,000 each.

The company doesn’t sell many of these units at the moment, Schumacher said last month, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

In midday trading, shares of the company were flat at US$4.80.

View full PBIO profile View Profile

Pressure BioSciences Inc. Timeline

Related Articles

An illustration of Ozop's BLIF technique
March 31 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
pills
April 13 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use